Kyowa Kirin Inc.- U.S. Revenue and Competitors

Claim your profile

Bedminster, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Kyowa Kirin Inc.- U.S.'s estimated annual revenue is currently $81.2M per year.(i)
  • Kyowa Kirin Inc.- U.S.'s estimated revenue per employee is $190,620

Employee Data

  • Kyowa Kirin Inc.- U.S. has 426 Employees.(i)
  • Kyowa Kirin Inc.- U.S. grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4180M1730013%$550MN/A
#2
$4.8M24-23%N/AN/A
#3
N/A3321%$70MN/A
#4
$8.2M41-2%N/AN/A
#5
$38500M914242%N/AN/A
#6
$34.4M171N/AN/AN/A
#7
$34.8M173-14%N/AN/A
#8
$40.6M202-11%N/AN/A
#9
$5.4M27N/AN/AN/A
#10
$0.4M2N/AN/AN/A

With US headquarters in Bedminster, NJ, Kyowa Kirin is a growing specialty pharmaceutical company focused on developing and commercializing prescription medicines that help improve the health and well-being of people through innovative drug developments and state-of-the-art technologies in oncology, nephrology, and immunology. For more information, you can visit us at www.kyowa-kirin.com.

keywords:N/A

N/A

Total Funding

426

Number of Employees

$81.2M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kyowa Kirin Inc.- U.S. News

2022-04-20 - Mycosis Fungoides Treatment Market Size, Scope And ...

Kyowa Kirin Co. Ltd., Pfizer Inc., Astellas Pharma, Bayer AG, Elorac Dover Medical and Scientific Equipment, Ltd. This Mycosis Fungoides...

2022-04-17 - Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights ...

Kolon TissueGene, the license holder for TG-C in the US (not TG-C LD), ... Ardelyx Inc. and Kyowa Kirin Co., Ltd. amended their 2017...

2022-04-06 - Ardelyx and Kyowa Kirin Amend License Agreement for ...

WALTHAM, Mass., April 11, 2022 /PRNewswire/ -- Ardelyx Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,...

2019-09-12 - Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)

10, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE), ... Crysvita is approved by the U.S. FDA, Health Canada, and Brazil's National Health ... Kyowa Kirin and Ultragenyx have been collaborating in the ...

2019-09-12 - Kyowa Kirin, Inc. to Double Number of Dreams it Fulfills With ...

Kyowa Kirin, Inc., a global specialty pharmaceutical company, has ... and our collaboration with Dream Foundation allows us to live our values ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$194.7M5011%N/A
#2
$145.7M689-22%$122.8M
#3
$171.6M92425%N/A